• Konopí magazine
Cannathemag
  • News
  • Magazine
  • Advertising
  • About Us
  • Language Services
  • Contacts
  • Search
  • CZCZ
Facebook Instagram

Successful Clinical Uses of CBD-rich Extracts in Covid-19 Patients

24. May 2021 | Category: Health
Medical cannabis.

Medical cannabis.

Researchers in a hospital in Klagenfurt, Austria, reported earlier this year that Covid-19 patients in the local intensive care unit experienced alleviation of inflammation and faster recovery after experimental administration of cannabidiol (CBD).

During three weeks of their standard treatment, patients were initially administered 200 milligrams of CBD broad-spectrum extract daily, but the dose was gradually increased to 300 mg.

“Blood tests after cannabidiol administration have shown that the rate of inflammation in patients is reduced. Those who received CBD were released earlier compared to those who did not receive it,” said the head of the Klagenfurt ICU, Rudolf Likar. “Apparently, CBD supports immunity.”

The success of the treatment might be due to the fact that some CBD-rich extracts can suppress viral cell entry and spread by inhibiting the expression of angiotensin-converting enzyme II (ACE2) receptors, which the SARS-CoV-2 spike glycoprotein binds to. These receptors are expressed in lung tissue as well as oral and nasal mucosa, the kidneys, testes and gastrointestinal tract.

Outperforming conventional drugs

In addition, the anti-inflammatory effects of CBD extracts reportedly outperform conventional drugs, since cannabidiol can cross the blood-brain barrier more easily and thus prevent some of the serious neurological consequences associated with long-term coronavirus infection.

Research into the impact of CBD on inflammation at the Klagenfurt clinic is not over, but the preliminary results appear to be very promising. “We are currently assessing the data, and they look quite good. We will probably start administering cannabidiol to all patients simply because it has no side effects,” added Likar. 

A similar study on the effectiveness of Covid-19 treatment with CBD-rich cannabis extracts is now underway in Israel. Meanwhile in Australia, drug developer Incannex has been evaluating the anti-inflammatory capabilities of its lead drug candidate IHL-675A against sepsis-associated acute respiratory distress syndrome (SAARDS) – the leading cause of death in patients who have contracted the Covid-19 virus. IHL-675A is a combined formulation of CBD and the anti-malaria drug hydroxychloroquine. In November, the company revealed positive animal study results that showed IHL-675A outperformed CBD significantly across the five inflammatory cytokines analyzed.

Author: Martin Helcman

 

 

 

 

 

Source: Cannabis Therapy Vol. 2

Take a quick look at this preview of the contents:

 

Feel free to read, share and download here. Enjoy!

Ohodnoťte tento článek
CBDcoronavirusCOVID-19

You might like

  • Illustration: Lazybastard.cz Health

    Wheelchair and Weed: When online prescriptions are covered by health insurance

  • Health

    Infographic: How to choose a THC:CBD ratio

  • Source: unsplash.com Health

    First Encounters with the Effects of Cannabis

Write comment Cancel

Search

Latest News

  • Robert Veverka in front of Regional Court Ostrava.

    Czech publisher sentenced for writing on cannabis

    13. March 2023
  • Illustration: Lazybastard.cz

    Wheelchair and Weed: When online prescriptions are covered by health insurance

    15. January 2022
  • In the courtroom. Photo: Frantisek Kuba

    Writing about Cannabis Is a Crime in the Czech Republic!

    16. November 2021
  • Robert Veverka in hemp field.

    Czech Journalist Prosecuted for “Inciting Toxicomania”

    8. November 2021
Cannabis Therapy on Facebook
  • Advertising
  • Magazine
  • About Us
  • Contacts
  • Terms and Conditions

CANNABIS THERAPY

Magazine about medical uses of cannabis. For patients, health professionals as well as general public. Free of charge.

Contact: office@konomag.cz

Tel.: +420 737 300 375

CATEGORIES

  • Advice
  • Breaking News
  • Health
  • Inspiration
  • Interviews
  • Leaves of Grass
  • News
  • Pharmacopeia
  • Pharmacopoeia
  • Press Release
  • Research Reports
  • Uncategorized
  • Veterinary Medicine

LATEST NEWS

  • Robert Veverka in front of Regional Court Ostrava.

    Czech publisher sentenced for writing on cannabis

    13. March 2023
  • Illustration: Lazybastard.cz

    Wheelchair and Weed: When online prescriptions are covered by health insurance

    15. January 2022

SEARCH

Follow us

Facebook Instagram
  • © 2018-23 CANNABIS THERAPY magazine. All rights belong to their respective owners. Without their written consent it is prohibited to use parts or whole works in any way, particularly spreading and copying, mechanically or electronically, in English, Czech or any other language.

  • Cannathemag

    Manage consent to cookies
    We use technologies such as cookies to store and/or access device information. We do this to improve your browsing experience and display personalized ads. Consenting to these technologies will allow us to process data such as browsing behavior or a unique ID on this website. Disagreeing or withdrawing consent may adversely affect certain features and functions.
    Functional Always active
    Technical storage or access is absolutely necessary for the legitimate purpose of enabling the use of a specific service that the subscriber or user has expressly requested, or for the sole purpose of carrying out the transmission of a message via an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    Technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    Technical storage or access is necessary to create user profiles in order to send advertising or track the user across a website or several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    Show preferences
    {title} {title} {title}
    Are you 18+?

    This website requires you to be of legal age. By clicking Yes, you verify you are at least 18 years old.